The gut microbiome can play an important role in maintaining homeostasis
in the human body. An imbalance in the gut microbiome can lead to pro-inflammatory
immune responses and the initiation of disease processes, including cancer.
Lymphocytes play a significant role in the reaction to bacterial colonization, mainly by
prompting a safe reaction to initiation. Most immunologically inhabitant cells are
continually signaled by dendritic cells or other antigen-presenting cells that collect
intestinal samples. Therefore, the microbiota is a pivotal contributor to developing
lymphoma, and specific changes to microbiota composition could help prevent the risk.
Microbial morphology can affect and control humanoids. The difference in the
composition of these microbes is associated with tumor development. Moreover, with
the increased exploration and knowledge of the connection between human microbiota
and carcinogenesis, the use of these findings to predict, prevent, or diagnose
lymphomas has attracted great attention. Probiotics have gained increasing medical
significance due to their beneficial effect on the human body, which has been linked to
the prevention and support of the treatment of many chronic diseases, including cancer,
in the absence of side effects. Chemotherapy and immunotherapy are extensively used
for the treatment of lymphomas. But these treatments have various side effects. There
is much evidence that probiotics can help in preventing cancer and support anticancer
therapy. This chapter presents the latest advances in research into the effectiveness of
probiotics in the prevention and treatment support of lymphoma. In addition, the
chapter also describes the potential mechanisms of probiotic chemoprevention and the
advisability of using probiotics in the prevention of lymphoma.
Keywords: B and T cell lymphoma, Chemotherapy, Immunotherapy, Immune checkpoint inhibitors (ICIs), Lymphocytes, Microbiota, Probiotics.
